Metabolizer phenotype prediction in different Peruvian ethnic groups through CYP2C9 polymorphisms
Author:
Valencia Ayala Edward12ORCID, Chevarría Arriaga Mylenka2, Coelho Eduardo Barbosa3, Sandoval José Sandoval4, Granara Alberto Salazar25ORCID
Affiliation:
1. Facultad de Medicina Humana, Universidad de San Martin de Porres, Centro de Investigación en Infectología e Inmunología-Instituto de Investigación , La Molina , Lima , Peru 2. Facultad de Medicina Humana, Universidad de San Martin de Porres, Centro de Investigación de Medicina Tradicional y Farmacología-Instituto de Investigación , La Molina , Lima , Peru 3. Departamento de Clínica Médica, Disciplina de Nefrologia , Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo , Ribeirao Preto , Brazil 4. Facultad de Medicina Humana, Universidad de San Martin de Porres, Centro de Investigación en Genética y Biología Molecular-Instituto de Investigación , La Molina, Lima , Peru 5. Facultad de Medicina Humana, Universidad de San Martin de Porres, Centro de Investigación de Medicina de Altura-Instituto de Investigación , La Molina, Lima , Peru
Abstract
Abstract
Objectives
The CYP2C9 gene have three common alleles, CYP2C9*1, CYP2C9*2 and CYP2C9*3, associated with different homozygous (*1/*1, *2/*2 and *3/*3) and heterozygous (*1/*2 and *1/*3) genotypes, which in turn are related to extensive (gEM), intermediate (gIM) and poor (gPM) metabolizers. Likewise, the inter-ethnic variability was intimately associated with different drug metabolism. Therefore, the aim of the present study was predict the metabolizer phenotypes in different Peruvian ethnic groups from lowland (<2,500 m) and highland (>2,500 m).
Methods
TaqMan genotyping assays were performed in a group of 174 healthy unrelated Peruvian individuals.
Results
In this study, the allelic comparison between the three eco-regions showed that the CYP2C9*1 was the most common in Andean (96.32%); the *2 was the most frequent in Coast (7.45%, p<0.05). Regarding the *3 was the most common in Amazonian (6.25%, p<0.05). In a corroborative manner, the gEM was the most common in Andean (94.74%), the gIM in Coast (17.02%) and gPM in Amazonian (6.25%) populations.
Conclusions
Our study provides a valuable source of information about to metabolizer phenotype drugs in different Peruvian ethnic groups. In this way, it could be established suitable genetic-dosage medicaments for various common diseases in these heterogenetic populations.
Publisher
Walter de Gruyter GmbH
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference70 articles.
1. Rendic, S, Di Carlo, FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:413–580. 2. Xie, HG, Kim, RB, Wood, AJJ, Stein, CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41:815–50. 3. Shimada, T, Yamazaki, H, Mimura, M, Inui, Y, Guengerich, FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Therapeut 1994;270:414–23. 4. Inoue, K, Yamazaki, H, Imiya, K, Akasaka, S, Guengerich, FP, Shimada, T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 1997;7:103–13. 5. Céspedes-Garro, C, Fricke-Galindo, I, Naranjo, ME, Rodrigues-Soares, F, Fariñas, H, de Andrés, F, et al.. Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. Expet Opin Drug Metabol Toxicol 2015;11:1893–905.
|
|